Product/Composition:- | Naproxen tablets(CR) |
---|---|
Strength:- | 375 mg, 500 mg, 750 mg |
Form:- | CR tablets |
Reference Brands:- | Naprelan(US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Naproxen CR tablets inhibit cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin production, which alleviates pain and inflammation. The controlled-release formulation provides long-lasting effects, reducing dosing frequency. Benefits include sustained relief from arthritis pain, inflammation, and fever, with improved compliance and a reliable safety profile when used as directed.
Naproxen CR (Controlled Release) tablets are approved in the EU and US for pain, inflammation, and rheumatoid arthritis. In the EU, brands like Naprelan are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data, with generic versions available. Both regions require detailed dossiers for initial approval and ongoing pharmacovigilance. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support efficient market access for naproxen CR tablets, ensuring adherence to European and American standards for safe, effective anti-inflammatory therapy.